{"doi":"10.1210/clinem/dgaf658","title":"Anti-Mullerian Hormone and Collagen Type I C-telopeptide Predict Fast, Imminent Bone Loss in Early Perimenopause: SWAN","abstract":"CONTEXT: Faster menopause-related bone mineral density (BMD) decline predicts more fractures. OBJECTIVE: Examine anti-Mullerian hormone (AMH) and collagen type I C-telopeptide (CTX) as predictors of fast, imminent BMD loss (BMD decline rate, over the next 1-2 years, ≥mean, annual menopause rate). DESIGN: Repeated measures modified Poisson regression estimated the associations of early perimenopausal levels of (1) AMH or CTX (in separate models), or (2) AMH and CTX (in a single model) with fast, imminent BMD loss. SETTING: Study of Women's Health Across the Nation (community-based cohort). PARTICIPANTS: A total of 436 early perimenopausal women. MAIN OUTCOME MEASURES: Fast, imminent BMD loss (at lumbar spine [LS], femoral neck [FN], or total hip [TH]). RESULTS: In separate models, adjusted for age, body mass index, cigarette use, race/ethnicity and study site, lesser AMH or greater CTX individually related to greater fast, imminent BMD loss risk. As predictors in a single model, lesser AMH and greater CTX remained independently associated with fast, imminent BMD loss. Per SD decrement in log-transformed AMH, fast BMD decline risk was 45% (LS), 17% (FN), and 26% (TH) greater (each P < .0001). Per SD increment in log-transformed CTX, fast BMD loss risk was 35% (LS), 23% (FN), and 34% (TH) greater (each P < .0001). Model areas under the curve was greater for models with AMH and CTX vs those for models with AMH or CTX individually (P < .001 for each BMD site-specific comparison). CONCLUSION: Combining AMH and CTX affords stronger prediction of fast, imminent BMD loss than using AMH or CTX individually.","journal":"The Journal of Clinical Endocrinology & Metabolism","year":2025,"id":535789,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.965,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":284567,"name":"Arun S. Karlamangla","orcid":"0000-0003-2293-6064","position":1,"is_corresponding":false},{"id":490182,"name":"Fatma Gossiel","orcid":"0000-0002-1433-2001","position":2,"is_corresponding":false},{"id":315519,"name":"Richard Eastell","orcid":"0000-0002-0323-3366","position":3,"is_corresponding":false},{"id":284569,"name":"Sherri‐Ann M. Burnett‐Bowie","orcid":"0000-0002-0064-096X","position":4,"is_corresponding":false},{"id":284575,"name":"Gail A. Greendale","orcid":"0000-0003-1054-1081","position":5,"is_corresponding":false},{"id":656436,"name":"Albert Shieh","orcid":"0000-0002-0695-7976","position":0,"is_corresponding":true}],"reference_count":66,"raw_metadata":null,"created_at":"2026-07-19T02:52:00.885532Z","pmid":"41399290","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}